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Receptor afﬁnityPrevious studies have demonstrated that HIV-1 develops resistance to CCR5 antagonists by gaining the
ability to use drug-occupied co-receptor. However, the effects of CCR5 antagonists on the afﬁnity of virus-co-
receptor interactions have been difﬁcult to quantify. We developed a pharmacological model for allosteric
interaction at G-protein coupled receptors to analyze the effect of different CCR5 antagonists on infection by
three laboratory adapted viruses with low, moderate and high susceptibility to the inhibitors. Infection data
for these viruses ﬁtted a model in which susceptibility to inhibition by CCR5 antagonists was directly related
to fold reduction in virus afﬁnity for CCR5. Dissociation constants for CCR5 antagonists calculated from the
modeled data were consistent with values obtained by standard methods, suggesting that this approach can
quantify pharmacologically relevant changes in co-receptor:ligand afﬁnity in the context of infection of
whole cells by authentic HIV-1 particles.
© 2009 Elsevier Inc. All rights reserved.Introduction
The two major coreceptors for HIV-1, CCR5 and CXCR4, are
members of the G-protein coupled receptor family. CCR5-tropic HIV-
1 predominates early in infection, whereas CXCR4-tropic HIV-1 is
more frequent in later stages of infection in some patients. Both
CCR5-tropic and CXCR4-topic HIV-1 infect cells by a similar multi-
step process; after binding to CD4 on the cell surface and undergoing
structural rearrangement to expose the V3 loop and bridging sheet
domains, one or more gp120 subunits in the trimeric HIV-1 spike
interact with CCR5 or CXCR4 coreceptor, triggering the ﬁnal gp120
rearrangements that result in release of gp41, membrane fusion and
virus entry.
Synthetic small molecule antagonists of CCR5, such as vicriviroc
(VCV, SCH 417609, SCH-D), maraviroc (MVC, UK-427,857) and
aplaviroc (APL, GW873140), have been shown to blockHIV-1 infection
in vitro and to reduce viral loads in vivo. These three structurally
diverse compounds have been shown to bind to CCR5with nM afﬁnity
in cell free assays (Dorr et al., 2005; Maeda et al., 2004; Strizki et al.,on).
ll rights reserved.2005) and to block HIV-1 entry with nM potency (IC50, half-maximal
inhibitory concentration) in cell-based assays (Watson et al., 2005).
The molecular pharmacology of VCV, MVC and APL has been
characterized extensively through analysis of their effects on binding
and signaling of chemokine ligands such as CCL3 (MIP-1α), CCL4
(MIP-1β) and CCL5 (RANTES). These studies support amodel in which
binding of the small molecule antagonist to an allosteric site on CCR5
results in reduced afﬁnity of the receptor for chemokine ligand
binding at the orthosteric site (Strizki, 2008; Wu et al., 1997).
Resistance to CCR5 antagonists in most cases is accompanied by
sequence changes in the V3 loop of gp120, the primary domain
involved in interaction with CCR5 (Marozsan et al., 2005; Ogert et al.,
2008; Trkola et al., 2002; Westby et al., 2007). However, mutations in
gp41 also have been shown to contribute to resistance to CCR5
antagonists in one lab-adapted VCV-resistant strain (Anastassopoulou
et al., 2009; Berro et al., 2009; Marozsan et al., 2005). These
observations suggest that development of resistance may involve
sequence changes that affect both binding to antagonist-occupied
CCR5 and structural transitions involved in fusion.
In functional assays, HIV-1 resistance to CCR5 antagonists is most
often associated with reduction in the maximum level of inhibition
rather than with reduction in compound potency, i.e., as “plateauing”
of the inhibition curve below 100% rather than as an increase in IC50
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Plateauing of inhibition curves indicates that resistant HIV-1 retains
partial ability to infect cells in the presence of saturating levels of CCR5
antagonist. Several studies also have demonstrated that measures of
susceptibility to CCR5 antagonists are affected by factors such as cell
type, receptor levels and single round vs. multi-round format, and
receptor density (Pugach et al., 2007; Pugach et al., 2009; Westby
et al., 2007).
Previous work by Pugach et al. (2007) showed that the general
shape of inhibition curves was consistent with simulations based on
pharmacological models for allosteric interaction such as those used
for chemokine studies. However, it has not been demonstrated that
suchmodels can be used to ﬁt and analyze actual HIV-1 infection data.
We considered that pharmacological models similar to those used for
chemokine studies might be used for analysis of HIV-1 interaction
with CCR5 antagonists. Such pharmacological models are generallyFig. 1. Comparison of binding and operational models for allosteric interaction of chemokine
interaction between a radiolabeled chemokine ⁎A and CCR5 antagonist B as described
Experimental variables are shown outside the gray box; the radioactive label on ⁎A provid
reciprocals of the equilibrium dissociation constants KA and KB. α is the allosteric cooperati
between a chemokine A and CCR5 antagonist B as described in Introduction. Afﬁnity constant
concentration of chemokine A at which response is half-maximal. (C) Simulated chemokine
EC50 and the incremental shifts for the indicated concentrations of CCR5 antagonist B relatiused to characterize drug action; however, they also provide
information about the relative afﬁnity of the chemokine for free
(unoccupied) vs. drug-occupied receptor. How this information is
obtained and the rationale for using such methods for investigation of
HIV resistance to CCR5 antagonists are described below.
The Allosteric Ternary Complex Model (ATCM, (Ehlert, 1988)) is a
well-established pharmacological model which has been used for
analysis of the effects of CCR5 antagonists on chemokine ligands
(Watson et al., 2005). The ATCM is the simplest model that can
describe allosteric interaction between an orthosteric (signaling)
ligand (e.g., MIP-1α) and an allosteric modulator (e.g., CCR5
antagonist). As depicted in the scheme in Fig. 1A, both the orthosteric
ligand (“A”, see Glossary, Table 1) and the allosteric modulator (“B”)
can bind to receptor (“R”). A and B can bind simultaneously to their
respective sites on R (hence “ternary complex”); however, occupancy
of the allosteric site on R by B inﬂuences the afﬁnity of the orthosterics with CCR5. (A) The Allosteric Ternary Complex Model (ATCM) is applied to analysis of
in Introduction. The gray box indicates interactions that are not directly observed.
es a “window” on binding of chemokine. Afﬁnity constants are shown in the ﬁgure as
vity factor. (B) An ATCM-based operational model is applied to analysis of interaction
s are as deﬁned in panel A and rate constants are as described in Introduction. EC50 is the
responses curves for the experiment shown in panel B, showing the maximum shift in
ve to its equilibrium dissociation constant KB.
Table 1
Glossary of terms used in operational models.
Orthosteric site Site on receptor which binds ligand giving biological response
Allosteric site Site on receptor which binds allosteric modulator
A Orthosteric ligand (e.g., chemokine)
B Allosteric modulator (e.g., CCR5 antagonist); binds to allosteric site and alters afﬁnity of receptor for orthosteric ligand
R Receptor (e.g., CCR5)
KA Equilibrium dissociation constant for complex of orthosteric ligand A and receptor R; location parameter for logistic binding curve
1/KA Afﬁnity constant for interaction of orthosteric ligand A with receptor R; reciprocal of dissociation constant KA
KB Equilibrium dissociation constant for complex of allosteric modulator and receptor R; reciprocal of dissociation constant KB
1/KB Afﬁnity constant for interaction of allosteric modulator B with modulator B and receptor R; reciprocal of afﬁnity constant 1/KB
K1…n Apparent rate constants for steps in biological response following binding of ligand A to receptor R
EC50 Concentration of orthosteric ligand A giving half-maximal biological response (e.g., Ca++ ﬂux) in absence of allosteric modulator, comprising
all rates (k1…n) and afﬁnity terms (1/KA) involved in the response; location parameter for logistic response curve
Alpha (α) Allosteric cooperativity factor; maximum fold change in afﬁnity constant for orthosteric ligand A when R is fully occupied by B; maximum fold
change in afﬁnity constant for allosteric modulator B when R is fully occupied by A
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between A and B, which is reﬂected in the square arrangement of the
linked equilibria in Fig. 1A, is the fundamental concept of the ATCM. A
key point related to the linked interactions of orthosteric ligand and
allosteric modulator at the receptor is that the orthosteric ligand can
be used as a “probe” to report receptor occupancy by the modulator
(Christopoulos and Kenakin, 2002; May et al., 2007).
In the ATCM, the fractional occupancy at each site on the
receptor is governed by the concentration of each ligand, their
respective afﬁnities for R, shown in Fig. 1A as 1/KA and 1/KB (see
Glossary, Table 1 and Supplementary Material), and an additional
term α, called the allosteric cooperativity factor (for a review, see
(May et al., 2007)). Alpha (α) represents ratio of the afﬁnity of each
ligand (A or B) for R when it is occupied by the other ligand (i.e.,
present as RB or AR) compared to when it is unoccupied (i.e.,
present only as R). With this deﬁnition, the afﬁnity for occupied
receptor can be expressed as an α-multiple of each ligand's afﬁnity
for unoccupied receptor. Thus, the afﬁnity of orthosteric ligand A for
unoccupied receptor R is 1/KA and its afﬁnity for modulator-
occupied receptor RB is α×(1/KA) or α/KA. Likewise, the afﬁnity of
modulator B for unoccupied R is 1/KB and its afﬁnity for orthosteric
ligand-occupied receptor AR is α/KB. It should be noted that the
afﬁnity terms are the reciprocals of the equilibrium dissociation
constants (see Table 1). This is important because both terms are
useful for discussing the ATCM and consequently both are used in
the literature (Christopoulos and Kenakin, 2002; Ehlert, 1988;
Kenakin, 2004a; May et al., 2007) and in this study. The value of
α is speciﬁc to the interaction of the orthosteric ligand and allosteric
modulator used in the experiment. We therefore reasoned that
calculation of α for different viruses and CCR5 antagonists could
provide a quantitative measure of the ratio of virus afﬁnity for free
vs. antagonist-occupied coreceptor.
The standard ATCM generally is used for modeling data from
equilibrium binding experiments using receptor-containing mem-
brane preparations. However, approaches also have been developed
that apply the conceptual framework of the ATCM to allosteric
interactions with receptors on live cells or tissues. Such “operational
models”, as they are termed in the pharmacology literature,
incorporate the linked equilibrium concept of the ATCM into an
interaction scheme in which the allosteric modulator causes a shift in
the orthosteric ligand response curve. If the orthosteric ligand and
allosteric modulator interact according to the ATCM, values for KB and
α can be calculated from the shifts in the response curves.
The relationship of an operational model to the standard ATCM
and how each is used to determine ligand afﬁnity and allosteric
cooperativity can be seen by comparison of the experimental designs
and methods of analysis. In the equilibrium binding experiment (Fig.
1A), use of a radiolabeled orthosteric ligand (⁎A) such as [125I]MIP-1α
allows measurement of total ⁎A bound to receptor-containing
membrane preparations. In the absence of CCR5 antagonist (top lineof the scheme), fractional binding of ⁎A (ρA) will follow a sigmoid
(logistic) concentration response curve given by:
ρA; B½ =0 =
4A½ 
4A½  + KA
ð1:1Þ
where [⁎A] is the concentration of radiolabeled chemokine and KA is
its equilibrium dissociation constant whose value is to be derived (see
Glossary, Table 1). Fitting the binding data for ⁎A to Eq. (1.1) provides
the “location parameter” or inﬂection point of the logistic curve,
which is also the concentration of ⁎A that gives 50% receptor
occupancy. In the absence of allosteric modulator B, the location
parameter occurs at [⁎A]=KA (see Eq. (1.1) and Fig. 1A). The Hill
slope of the curve will be 1 if the binding stoichiometry is 1:1.
We next consider interaction of ⁎A with R as the concentration of
allosteric modulator B is increased. If the afﬁnity of chemokine ⁎A for
modulator-occupied receptor RB is less than its afﬁnity for R, higher
concentrationsof ⁎Awill be required to achieve 50% receptor occupancy
by ⁎A and therefore the binding curves will shift to the right. The
magnitude of the rightward shift is a function of [B], its equilibrium
dissociation constant KB and the allosteric cooperativity factor α:
DR =
1 + B½ KB
1 + α B½ KB
ð1:2Þ
In the ATCM, theDR term (dose ratio, (Kenakin, 2004a)) functions as a
multiplier of location parameter KA as shown below:
ρA;B =
4A½ 
4A½  + KA DRð Þ
ð1:3Þ
As the concentration of CCR5 antagonist increases, the value of DR
increases and the binding curves shift to the right (see Supplementary
Figure 1). The equation for the ATCM (Eq. (1.3)) usually is derived
from the equilibria in Fig. 1 and is written using the expanded form of
DR shown in Eq. (1.2) (see (Kenakin, 2004a) and references therein).
We have used the DR term here to emphasize the fact that in the
ATCM, the effect of allosteric modulator is only on the location
parameter KA and not on any other parameters of the curve such as
the height (range) or Hill slope.
Fitting the binding curves obtained for ⁎A at increasing [B] to Eq.
(1.3) allows calculation of KA, KB and α. In the absence of CCR5
antagonist, i.e., when [B]=0, DR is equal to 1 and Eq. (1.3) reduces to
Eq. (1.1). DR reaches a limit of 1/αwhen CCR5 antagonist is saturating
(i.e., when [B]→∞). Under these conditions, Eq. (1.3) reduces to:
ρA; B½ Y∞ =
4A½ 
4A½  + KAα
ð1:4Þ
The location parameter in Eq. (1.4) is KA/α, indicating that 50%
receptor binding now occurs at [⁎A]=KA/α (see Fig. 1A). Recalling
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tion constant (KA/α), if the midpoint of the ﬁtted binding curve for ⁎A
shifts to the right by 2 log10 units when CCR5 antagonist B is
saturating (i.e., KA/α=100×KA), it indicates that antagonist B
reduces the afﬁnity of CCR5 for chemokine ⁎A by 100-fold (i.e.,
α=0.01). Likewise, if the binding curve shifts rightward by 1 log10
unit when B is saturating, it implies a 10-fold reduction in chemokine
afﬁnity (α=0.1)
An operational model based on the ATCM allows calculation of KB
and α from shifts in biological response curves rather than binding
curves. Importantly, knowledge of KA is not required for calculation of
α. In the biological response experiment shown in Fig. 1B, binding of
chemokine A to CCR5 (R) triggers molecular interactions in a signal
transduction pathway leading to calcium mobilization (for a review,
see (Oppermann, 2004)). Analogous to the binding experiment, the
orthosteric ligand is used as a “probe” to measure receptor occupancy
by the allosteric modulator (May et al., 2007). The increase in
cytoplasmic Ca++ can be monitored using a calcium-sensitive
ﬂuorescent dye (top line, Fig. 1B, see also (Watson et al., 2005)).
Under suitable experimental conditions, chemokine A produces a
saturable response curve that can be ﬁt to a logistic equation:
E
Emax
=
A½ nH
A½ nH + EC50ð ÞnH
when B½  = 0 ð2:1Þ
where E represents the response (ﬂuorescent signal) obtained at a
given concentration of chemokineA and Emax represents themaximum
response. By deﬁnition, the location parameter of the curve is the half-
maximal effective concentration of orthosteric ligand (EC50, see
Glossary, Table 1).
Note that Eq. (2.1) has the same form as Eq. (1.1), except that EC50
is used in place of KA and the Hill slope (nH) is deﬁned by empirically
by ﬁtting the response curves (May et al., 2007). EC50 and nH are
parameters that characterize the overall process involved in the
response (ﬂuorescent signal) to chemokine A, comprising its inter-
action with CCR5, the rates of the downstream steps (k1…n) and any
cooperativity affecting the Hill slope of the response curve (for a
review see (Kenakin, 2004b; May et al., 2007).
In the response experiment, if CCR5 antagonist B affects only the
binding of chemokine A to CCR5 (R) and does not affect binding
cooperativity or the rates of the downstream steps k1…n and if R is not
limiting, i.e., if A and B interact according to the assumptions of the
ATCM, the effect of B on the response curves is given by:
E
Emax
=
A½ nH
A½ nH + EC50ð ÞnH DRð Þ
ð2:2Þ
whereDR is deﬁned as in Eq. (1.2). As in the bindingmodel, increasing
[B] will increase the value of DR, shifting the response curves to the
right (Fig. 1C). The value of DR reaches a limit of 1/α when B is
saturating and thus the location parameter for half-maximal response
occurs at [A]=EC50/α when [B]→∞:
E
Emax
=
A½ nH
A½ nH + EC50ð ÞnHα
when B½ Y∞ ð2:3Þ
If chemokine A and CCR5 antagonist B interact according to the ATCM,
the response curves will shift in parallel (Kenakin, 2004a) and ﬁtting
the experimental data to Eq. (2.2) for the complete set of response
curves will give the values of EC50, nH, KB and α. By calculating the
value of α, the operational model provides a measure of the change in
chemokine afﬁnity for antagonist-occupied CCR5 vs. unoccupied CCR5
without needing to know the actual afﬁnity of the chemokine for
either form of the receptor. This forms the basis of our approach to
analysis of the change in coreceptor afﬁnity for HIV with varying
susceptibilities to CCR5 antagonists.
If the rates of the downstream steps k1…n or the Hill slope nH are
affected by A or B, or if R becomes limiting the response curves willshow complex changes rather than the parallel shifts predicted by the
ATCM. In this case, the shifts in the response curve cannot be attributed
solely to changes in afﬁnity, requiring use of more complexmodels for
analysis (Kenakin, Jenkinson, and Watson, 2006; May et al., 2007).
We show here that measurement of HIV infection of cells by ﬂow
cytometry yields parallel infection response curves that can be ﬁt to an
ATCM-based operational model for allosteric interaction, providing
estimates of the underlying antagonist dissociation constants (KB) and
allosteric cooperativity constants (α). These parameters can be used to
calculate inhibition curves for CCR5 antagonists, with good agreement
between calculated and observedmaximumpercent inhibition for the
test viruses. A key concept derived from the ATCM is the use of
allosteric modulators with known equilibrium dissociation constants
as a “probes” to investigate the binding of the orthosteric ligand, in
this case gp120 in the context of the trimer spike. For the viruses
analyzed in this study, the model suggests that inhibition of infection
by CCR5 antagonists is strongly correlated with the magnitude of
reduction in virus afﬁnity for drug-occupied coreceptor. The opera-
tional model represents a “base case” for analyzing interaction
between HIV and CCR5 antagonists under conditions where their
relative afﬁnities for CCR5 are themajor factors determining infection.
Alternative models and limitations of the approach are discussed.
Results
Development of an operational model for allosteric interaction of HIV-1
and CCR5 antagonists
Our starting point for development of an operational model for HIV
and CCR5 antagonists was the observation that plotting fraction of
p24+ cells vs. log10 virus dilution for varying concentrations of CCR5
antagonists yielded a family of parallel infection response curves. The
pattern of parallel shifts was especially evident when the curves were
plotted on a log-log scale or using the logit transform (see Supple-
mentary Fig. 1). Investigation of the possible basis of this phenomenon
led us to the pharmacological modeling literature reviewed in the
Introduction and the hypothesis that although HIV entry is a complex
multistep process (see (Melikyan, 2008) and references therein), data
from the single round infection assay described here might be
amenable to analysis using an ATCM-based operational model.
As shown in the scheme in Fig. 2A, gp120 on virus particle (V)
binds to CD4 rendering the particle (V’) competent to interact with
CCR5. The overall rate constant for this process, incorporating the
forward and reverse rates, is expressed as k1 in the ﬁgure. Cell-bound
virus also is susceptible to inactivation (Kuhmann et al., 2000; Platt,
Durnin, and Kabat, 2005) with rate kx. CD4-bound gp120 on V’ can
interact with a site on CCR5 (R) that overlaps the orthosteric binding
site used by chemokine ligands such as CCL3 (Blanpain et al., 1999a;
Lee et al., 1999), forming a complex which is competent to undergo
the subsequent steps leading to membrane fusion and virus entry. As
required by the ATCM, our model assumes that the rates of formation
and dissociation of complexes between V’ and CCR5 (R) on the cell
surface are in equilibrium, represented in the scheme by the constant
KV'. The rates of the steps downstream from formation of V’R complex
are shown as k2…n. Cell-bound virus in the V'R complex also is
assumed to be susceptible to inactivation at rate kx.
As described in the Introduction, if the assumptions for an ATCM-
based model are valid for the experimental conditions and the viruses
tested, plotting fraction of p24+ cells (fpos) vs. virus concentration
will generate a series of parallel infection response curves that can be
ﬁt to the logistic equation:
fpos =
V½ nH
V½ nH + f0:5ð ÞnH DRð Þ
ð3:1Þ
This equation has the same form as Eq. (2.2) in Introduction, except
that the location parameter is deﬁned here as f0.5, the virus
Fig. 2.Development of an operational model for allosteric interaction of HIV-1 and CCR5 Antagonists. (A) Operational model for HIV-1 interaction with CCR5. The gray box represents
portion of themodel derived from the ATCM. Themeaning of the letter symbols is described in the text. (B) Flow cytometric detection of p24+ cells (red symbols) in a background of
p24− cells (black symbols). RU570-PC was treated with the indicated concentrations of VCV. The fraction of p24+ cells detected by ﬂow cytometry is shown in each panel. (C) Shifts
in logit infection curves for viruses treated with increasing concentrations of VCV. The symbols show the logit fpos data at different concentrations of virus (x-axis) and VCV (indicated
by different symbols shown in the legend). The lines represent the logit fpos values obtained by ﬁtting the experimental data to the model using mathematical optimization.
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functionally analogous to EC50 as used the chemokine response
example. The DR term is deﬁned as in Eq. (1.2) in the Introduction. If
the assumptions of the ATCM apply, CCR5 antagonist will only affect
the location parameter and the infection curves will shift in parallel.
However, if the assumptions of an ATCM-based model are not valid,
i.e., if CCR5 becomes limiting or if the rates of the upstream,
downstream and inactivation steps (k1, k2…n, kx) or the Hill slope
(nH) are sensitive to changes in virus or CCR5 antagonist concentra-
tion, the response curves will not shift in parallel and it will not be
possible to ﬁt the data to the model.
Flow cytometry allows sensitive measurement of infection by authentic
HIV-1 particles
The accuracy of the values obtained from the operational model is
affected by the precision and reproducibility of our measurement of
the fraction of cells infected at the selected concentrations of virus and
CCR5 antagonist. We chose authentic infectious HIV-1 rather than
pseudotyped reporter virus for the studies and prepared large stocksto provide a consistent source of virus. The fraction of cells infected
was quantiﬁed by ﬂow cytometry. The protease inhibitor amprenavir
was used to restrict replication of infectious HIV-1 to a single round as
described by Mascola et al. (2002). We found that ﬂow cytometry
accurately and reproducibly detected small numbers of p24+ cells in
the presence of large numbers of p24− cells (Fig. 2B), allowing us to
set a limit of quantiﬁcation (LOQ) of ﬁve p24+ cells in 10,000 cells
counted (fpos=0.0005).
As illustrated in the chemokine response experiment (Fig. 1B),
determination of α and KB requires that the chemokine response data
can be ﬁt to a logistic curve, but does not require knowledge of the
number of chemokine molecules bound or the fraction of CCR5
receptors occupied, or in our case, the number of viruses that attach or
productively infect a cell. For the experiments, we used concentra-
tions of HIV-1 that infected less than 50% of the cells in the sample.
Working in this range provided data that could be ﬁt to the logistic
equation in our model and avoided problems such as cell clumping or
fragility at harvest which occurred at high levels of virus. It should be
noted that fpos represents the proportion of cells in the sample that
become infected (p24+). fpos increases with virus concentration [V]
Table 3
Alpha values obtained for CCR5 antagonists maraviroc and aplaviroc by modeling of
logit-transformed infection data.
Compound JV1083-PC RU570-PC JV1083-VCVres
MVC b0.0005 0.07 (0.03, 0.11) 0.82 (0.79, 0.86)
APL 0.003 (b0.0005, 0.008) 0.10 (0.05, 0.14) 1.05 (0.85, 1.25)
Values based on 3 independent experiments per virus; mean and 95% conﬁdence limits
are shown.
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methods). The number of viruses which attach to and productively
infect an average cell (i.e., the mulitiplicity of infection, m.o.i.) is
related to the concentration of viruses to which the cells are exposed.
Thus, fpos will be a function of m.o.i., which in turn is a function of [V]
just as the biological response to chemokine described in Introduction
is a function of the number of chemokine molecules to which a cell is
exposed.
Virus infection data can be ﬁt to an operational model for allosteric
modulation of co-receptor afﬁnity for HIV-1
Weuseda logit transformof the responsedata, log10(fpos/(1− fpos)),
analogous to that used byHill in his classic studies of oxygen binding to
hemoglobin, to facilitate ﬁtting data to the model across the 4-log
range of fraction infected observed in the experiments (see Supple-
mentary Figure 2). The logit transform generates a linear response
curve, allowing the CCR5 antagonist shifted response curves to be ﬁt as
a family of parallel lines. In Fig. 2C, the symbols represent the observed
log10(fpos/(1− fpos)) values and the lines represent the logit infection
curves calculated by the operational model. Logit infection curves for
JV1038-PC, RU570-PC and JV1083-VCVres shifted to different extents
with increasing concentrations of VCV. Rightward shifts were greatest
for JV1083-PC, where VCV concentrations N100 nM reduced the
fraction of p24+cells below the LOQ. Logit response curves for RU570-
PC shifted less than those of JV1083-PC and stacked up as VCV
concentration approached 10 μM. In contrast, logit response curves for
resistant virus JV1083-VCVres shifted slightly to the left at 10 μMVCV.
Fitting by mathematical optimization allows all of the data
obtained from the 7 virus and 8 VCV concentrations to be used
simultaneously in ﬁnding a global solution via Eq. (4.1), (4.2) and
(7.1) (Materials and methods) for the complete family of logit
response curves. A total of 56 conditions were analyzed in each
experiment, with 10,000 cells counted per condition. Coefﬁcients of
determination (r2) for the ﬁt of data to the model for each of the
curves shown in Fig. 1C were ≥0.90. Three independent experiments
were conducted for each virus, using frozen stocks of virus and cells.
Calculation of mean values of f0.5 and Hill slope (nH) for each virus
showed consistent infection responses over the series of experiments
(Table 2). Note that because we used virus concentrations that
infected b50% of the cells, the f0.5 values are calculated by the curve
ﬁtting algorithm rather than measured directly in the assay.
Coefﬁcients of variation (%CV) for the f0.5 and Hill slope values were
b11% and b7%, respectively, for all viruses. Values of f0.5, nH, KB and α
for each virus-CCR5 antagonist combination were based on ﬂow
cytometric analysis of a total 1,680,000 cells from three independent
experiments.
Fitting the logit infection data also provided estimates for the
allosteric cooperativity factor α, which deﬁnes the fold change in
CCR5 afﬁnity for each ligand in the presence of saturating levels of the
other ligand. The mean α value for JV1083-PC was below the LOQ for
the assay (Table 2), indicating that CCR5 afﬁnity for this virus was
essentially undetectable in the presence of saturating VCV. The mean
α value for RU570-PC was 0.08, indicating that CCR5 afﬁnity for this
virus was reduced by 92% in the presence of saturating concentrations
of VCV. In contrast, the mean α value for JV1083-VCVres was 1.2,Table 2
Parameters obtained for vicriviroc by modeling of logit-transformed infection data.
Virus Location, f0.5 Hill slope, nH Alpha (α)
JV1083-PC 1.38 (1.21, 1.54) 1.03 (0.95, 1.11) b0.0005
RU570-PC 3.58 (3.35, 3.81) 1.02 (1.01, 1.02) 0.08 (0.03, 0.12)
JV1038-VCVres 1.32 (1.17, 1.46) 1.10 (1.04, 1.16) 1.20 (1.11, 1.29)
Values based on 3 independent experiments per compound for each virus; mean and
95% conﬁdence limits are shown.indicating that afﬁnity of VCV-occupied CCR5 for this virus was 20%
higher compared to unoccupied co-receptor.
Alpha values obtained for the three viruses with maraviroc and aplaviroc
are similar to those observed with vicriviroc
We performed similar experiments using two other CCR5
antagonists, MVC and APL. The α values obtained for MVC and APL
interaction with the susceptible viruses JV1083-PC and RU570-PC
were not signiﬁcantly different than α values obtained for VCV. For
the resistant virus JV1083-VCVres, the α value for APL (1.05) was not
signiﬁcantly different from VCV (1.2). However, the α value for this
virus with MCV (0.82) was lower than with VCV and this difference
reached statistical signiﬁcance (pb0.05), suggesting that MVC had a
small but measurable effect on infection by JV1083-VCVres (Table 3).
CCR5 antagonist dissociation constants obtained using susceptible
viruses are consistent with literature values
The operational model allows calculation of dissociation constants
for CCR5 antagonists from the incremental rightward shifts in logit-
transformed infection curves as antagonist concentration is increased.
In the model, the magnitude and limiting value of the shifts is
dependent on CCR5 antagonist concentration, its equilibrium dis-
sociation constant, KB, and the allosteric cooperativity factor, α, via
the DR term (1+[B]/KB)/(1+α[B]/KB) in Eq. (1.2) (see Introduction).
The KB values generated by the model may be compared with
literature values from equilibrium binding studies to validate the
experimental approach used in the study.
We compared the KB values obtained using the operational model
for VCV, MCV and APL with values obtained from equilibrium binding
experiments using radiolabelled CCL3 (MPI-1α) and CCR5 mem-
branes (Watson et al., 2005). As shown in Table 4, the KB values for
VCV and MVC obtained using JV1083-PC and RU570-PC as “probes”
were not signiﬁcantly different from KB values obtained using CCL3.
The KB values for APL obtained using JV1083-PC and RU570-PC were
nearly identical, but were approximately 3-fold lower than values
obtained by Watson et al. using CCL3. However, the KB values for
other CCR5 antagonists were within the range of reported from
equilibrium binding studies (Price et al., 2006; Strizki et al., 2005;
Watson et al., 2005). As noted above, the shifts in the response curves
for JV1083-VCVres were very small (zero in some cases), precluding
use of this virus as a probe for measurement of KB values for these
CCR5 antagonists. The close agreement in KB values obtained withTable 4
Dissociation constants (KB) for CCR5 antagonists obtained by modeling of logit-
transformed infection data.
Compound JV1083-PC RU570-PC Literaturea
VCV 2.3 (1.9, 2.7) 2.5 (2.1, 3.0) 4.0 (2.5, 6.3)
MVC 1.6 (1.0, 2.1) 2.1 (1.3, 2.8) 2.0 (1.2, 3.1)
APL 0.8 (0.4, 1.2) 0.8 (0.5, 1.2) 2.5 (1.6, 3.2)
Units are in nM. Values based on 3 independent experiments per virus; mean and 95%
conﬁdence limits are shown.
a Values obtained from [125I]MIP-1α radioligand binding assay (Watson et al., 2005).
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suggests that the infection response data ﬁts our operational model
and that the α values reﬂect changes in afﬁnity of antagonist-
occupied CCR5 for susceptible HIV-1.
Afﬁnity modulation parameters from the operational model deﬁne
maximum shifts in virus infection response curves at saturating
VCV concentration
To illustrate the relationship between virus infection and the
change in CCR5 afﬁnity upon VCV binding, quantiﬁed by the α
parameter, we plotted the fraction of cells infected (fpos) for different
virus concentrations in the absence of VCV and at saturating levels of
VCV.
Fig. 3 shows the combined fpos data (symbols) from the three
experiments for each virus plotted on a log scale (y-axis). The
calculated infection curves (lines) for each virus were generated
using Eqs. (2.1) and (2.3), using the mean values of f0.5, nH and α from
Table 2. Virus concentration is plotted normalized to its f0.5 to facilitate
comparison of the effect of α across viruses.
There was good agreement between the calculated and experi-
mental fpos data for the most susceptible virus, JV1083-PC, in the
absence of VCV (Fig. 3A). At 10 μM VCV, infection by JV1083-PC was
completely suppressed. The value of α calculated by the model was
zero, i.e., below our limit of detection of 0.0005. The position of the
calculated infection curve for α=0.0005 is indicated by the dotted
line, which corresponds to a 2,000-fold decrease (1/0.0005) in CCR5
afﬁnity for JV1083-PC. Good agreement between calculated and
experimental datawas found for RU570-PC both in the absence of VCV
and at saturating VCV (Fig. 3B). The value of α calculated by the
operational model was 0.08, which corresponds to a 12-fold decrease
(1/0.08) in afﬁnity of CCR5 for RU570-PCwhen the co-receptor is fullyFig. 3. Modeling shifts in infection response curves and maximum percent inhibition. (A–C
absence of VCV (circles) or at 10 μM VCV (triangles). The values of fpos calculated for the abs
solid lines. Values of fpos calculated using Eq. (2.3) for inﬁnite VCV concentration using the m
A shows the calculation for JV1083-PC using α=0.0005. (D–E) The mean and standard error
the experimental relative inhibition data at each virus concentration are shown as symbol
VCVres at 10 μM VCV for each virus concentration are shown as symbols (squares). The solid
three viruses using Eq. (2.4) (Materials and methods).occupied by VCV. This was reﬂected in a 12-fold rightward shift in the
infection curve. Good agreement between calculated and experi-
mental fpos values also was found for JV1083-VCVres (Fig. 3C).
However, in contrast to the two susceptible viruses, JV1083-VCVres
showed a 0.2-fold leftward shift in location parameter (f0.5) suggest-
ing a 20% increase in afﬁnity for VCV-occupied CCR5 compared to
unoccupied CCR5 (α=1.2).
Afﬁnity modulation parameters from the operational model deﬁne
maximum percent inhibition by vicriviroc
We calculated MPI values for each of the viruses using Eq. (6.2)
(Materials and methods) and compared these to the MPI values
obtained by non-linear regression of individual relative inhibition
curves obtained at each virus concentration (see Materials and
methods). In Figs. 3D and E, the symbols and error bars represent
the mean and standard error for the upper asymptote of a 4-
parameter logistic ﬁt of the relative inhibition data for JV1083-PC and
RU570-PC, respectively. There was good agreement between the MPI
values calculated from the operational model and the MPI values
observed for the ﬁtted inhibition data. It was not possible to obtain
mean and standard error values for JV1083-VCVres (Fig. 3E) because
non-linear regression of the percent inhibition data did not converge
to a solution. Instead, the symbols represent the percent inhibition
obtained at 10 μM VCV. The calculated MPI values (solid line) for
JV1083-VCVres were consistent with the observed MPI values. Overall,
the modeled values for the infection curve shifts and MPI values were
in good agreement with the experimental data. MPI values obtained
for the viruses were not affected by virus concentration used in the
experiments. However, the operational model predicts that MPI
would be affected for viruses with αN∼0.2 at virus concentrations
N0.1× f0.5 (see Supplementary Figure 3).) Experimental data for fraction of cells infected (fpos) for the each virus is shown for
ence of VCV using Eq. (2.2) in text using the mean f0.5 values from Table 1 are shown as
ean f0.5 and α values from Table 1 are shown as solid lines (A, C); the dotted line in panel
maximum percent inhibition values obtained from a 4-parameter logistic regression of
s (circles) with error bars. (E) Experimental relative inhibition data for virus JV1083-
lines in Panels D–F indicate the maximum percent inhibition values calculated for the
Fig. 4. Comparison of experimental inhibition data and relative inhibition curves obtained from the model. (A–C) The mean and standard error for experimental relative inhibition
data for each of the viruses at 6 binned concentrations is shown as symbols and error bars. The solid lines represent the relative inhibition for each virus calculated using Eq. (2.1)
(Materials and methods) and the mean values of f0.5, nH and α from Table 1 and the mean VCV KB values obtained for each virus from Table 3.
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model are consistent with ﬁts obtained by non-linear regression of
inhibition data
HIV-1 susceptibility to CCR5 antagonists such as VCV generally is
deﬁned in terms of the maximum percent inhibition obtained with
increasing concentrations of CCR5 antagonist. We calculated relative
inhibition values using the fpos data from the three experiments
performed for each virus. We used Eq. (6.1) (Materials and methods)
to simulate inhibition curves using the parameters for f0.5, nH, α, and KB
in Tables 2 and 3. The means and standard errors of the experimental
relative inhibition data are shown as symbols and error bars in Fig. 4.
The solid line curves represent the relative inhibition values obtained
from the simulation using Eq. (6.1). Hill slopes for the inhibition curves
calculated by the model were equal to 1 for JV1083-PC and RU705-PC
and -1 for JV1083-VCVres. The experimental data also was ﬁt to
4-parameter logistic curves using nonlinear regression (see Supple-
mentary Figure 4). The Hill slopes of the curves obtained by non-linear
regression had wide conﬁdence intervals which overlapped the slopes
calculated by themodel except for twovirus concentrations for RU570-
PC and one from JV1083-PC (see Supplementary Figure 4). Non-linear
regression for JV570-VCVres failed to converge to a solution except for
one virus concentration; the 95% conﬁdence interval overlapped the
slope from the model. Comparison of the simulated curves generated
by the model to those generated by nonlinear regression of the
experimental data showed no statistically signiﬁcant difference
between the MPI values obtained by the two methods.
Discussion
We have shown that experimental data for the effect of VCV and
other CCR5 antagonists on HIV-1 infection can be ﬁt to an operational
model for allosteric interaction at GPCR. This model provides insight
into the relationship between the change in afﬁnity of a speciﬁc HIV-1
isolate for free vs. antagonist-occupied CCR5 and susceptibility of the
virus to inhibition by CCR5 antagonists. The keymodel parameter that
linksmaximum change in afﬁnitywithmaximumpercent inhibition is
the allosteric cooperativity factor, α. This factor quantiﬁes the
maximum change in afﬁnity of CCR5 for one ligand when the receptor
is fully occupied by the other ligand. The salient property of α is that
its value is speciﬁc for the two ligands interacting at the receptor,
allowing comparison of the effect of a speciﬁc CCR5 antagonist on
CCR5 afﬁnity of different viruses or the effect of different CCR5
antagonists on CCR5 afﬁnity for a speciﬁc virus.
The α parameter has been used previously to characterize
differences in the susceptibility of CCR5 chemokines to blockade by
various CCR5 antagonists. Watson et al. 2005 showed that VCV
blocked binding of CCL5 (RANTES) with α≤0.06, whereas binding of
this chemokine was minimally affected by APL (α=0.8). However,binding of CCL3 (MPI-1α) was blocked by VCV, APL andMCV (Watson
et al., 2005). In our study, infection by laboratory-adapted virus
JV1083-PC was completed blocked by VCV, MVC and APL (α≤0.003).
Infection by a laboratory-passaged resistant virus, JV1083-VCVres,
showed low but measurable susceptibility to MVC (α=0.8), whereas
APL had no effect (α=1.0) and VCV slightly enhanced infection
(α=1.2). Infection by laboratory-adapted virus RU570-PC was less
susceptible than JV1083-PC to inhibition by VCV, MVC and APL with α
values of 0.08, 0.07 and 0.10, respectively.
Equilibrium dissociation constants (KB) calculated using the
operational model for susceptible viruses JV1083-PC and RU570-PC
were similar to those reported from binding studies of MIP-1α
(Watson et al., 2005). These results suggest that the operational
model can generate pharmacologically appropriate values for KB and
α. The operational model assumes that interaction between orthos-
teric ligand and antagonist at the receptor can be described by the
linked equilibria of the ATCM. The similarity of the CCR5 antagonist
equilibrium dissociation constants to literature values suggests that
on-off interactions between virus and CCR5 approach or reach
equilibrium conditions. This is consistent with previous studies
showing that there is a considerable delay between binding of HIV-
1 to CD4 and subsequent steps that trigger virus entry (Miyauchi et al.,
2009). However, the values of KB are slightly lower than literature
values for VCV (2.4 nM vs. 4.0 nM, ns) and APL (0.8 nM vs. 2.5 nM,
pb0.5). These differences may reﬂect normal variability in measure-
ment. Alternatively, they may indicate that re-equilibration effects on
receptor occupancy cannot be completely ruled out. Such effects can
arise if the assay has a pre-equilibration step (i.e., before addition of
virus or chemokine) and if the off-rate for CCR5 antagonist is
sufﬁciently slow such that receptor occupancy is greater than it
would be under true equilibrium conditions (Kenakin, Jenkinson, and
Watson, 2006). The off-rate for APL is the slowest of the three CCR5
antagonists used in this study (Watson et al., 2005), and would be the
most likely to show re-equilibration effects. Conceptually, establish-
ment of net equilibrium between virus and cell may arise from
interaction of multiple gp120 molecules on CD4-bound virus with
multiple CCR5 molecules on the cell, a situation which would not
apply to chemokine ligands.
Interpretation of the shifts in infection curves in terms of changes
in afﬁnity requires that the CCR5 antagonist only affects virus binding
to CCR5 without affecting the rates of any other steps in the entry
process. In practical terms, this means that CCR5 and CD4 should not
be limiting and that the Hill slope of the infection curve should be
constant for all concentrations of CCR5 antagonist. For viruses that ﬁt
the model, maximum percent inhibition (MPI) should remain
essentially constant for virus concentrations less than 0.1× f0.5.
However, effects of CCR5 antagonist concentration and virus
concentration on MPI have been reported for speciﬁc viruses (Ketas
et al., 2007; Ogert et al., 2008). For example, resistant virus RU570-
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virus used in the assay (Ogert et al., 2008) and VCV-dependent
changes in the Hill slope of infection curves such that the infection
data cannot be ﬁt to the ATCM-based operational model described
here (Buontempo et al., unpublished observations). Factors such as
receptor level and mutations in gp41 also have been shown to affect
HIV response to CCR5 antagonists (Anastassopoulou et al., 2009; Berro
et al., 2009; Marozsan et al., 2005; Pugach et al., 2009). These studies
suggest that changes associated with resistance for some viruses may
involve factors other than afﬁnity of gp120 for CCR5.
The number of envelope trimer-CCR5 interactions per virion
required for infection is has been estimated to range from as few as
one (Klasse, 2007; Yang et al., 2005; Yang et al., 2006) to four-to-six
(Kuhmann et al., 2000) and up to ﬁve to eight (Klasse, 2007; Magnus et
al., 2009). Evaluation of various models by Klasse (Klasse, 2007) and
Magnus et al. (Magnus et al., 2009) suggests that the number of
interactions required may differ between viruses. Work by Platt et al
(Platt et al., 2007) suggests that a interaction of one gp120with CCR5 on
a single spike is sufﬁcient for infection by well-adapted viruses, but that
allosteric interactions within the trimer spike allow the same virus to
compensate for lowCCR5 concentrationor poorgp120-CCR5 interaction
by using multiple gp120-CCR5 interactions to trigger the entry process.
The ATCM-based operational model assumes that the constant Hill
slope remains constant and that the allosteric modulator only affects
the location parameter of the response curve. Our ability to ﬁt the
infection data (fpos) with constant Hill slopes suggests that the
stoichiometry of CD4:gp120 - CCR5 interaction does not change under
the conditions of the assay for the viruses studied. It is possible that
our experimental design is not sensitive to small changes in receptor
stoichiometry or the rates structural rearrangements leading to
fusion. However, we have identiﬁed at least one virus which does
not ﬁt the basic ATCM model, RU570-VCVres.
Of note, alternative models have been proposed that can ﬁt
infection data from a virus variant (D1/85.16) in which resistance
mapped to gp41 while V3 sequences were unchanged compared to
the susceptible parental virus (Anastassopoulou et al., 2009). The
model described by Anastassopoulou et al. is based on the hypothesis
that two (or potentially more) forms of CCR5 with varying afﬁnities
for CCR5 antagonists exist on the cell surface in different proportions.
Susceptible and resistant viruses interact differently with these
receptors in both their free and antagonist-occupied forms. This
model can accommodate more complex inhibition curves than the
ATCM-based model described here. In future studies it would
therefore be useful to evaluate viruses such as D1/85.16 using our
ATCM-based operational model to assess its ability to analyze the
effect of mutations potentially impacting steps downstream from V3
interaction with CCR5 or potentially preventing establishment of
equilibrium binding conditions.
Kenakin et al. have described a model for insurmountable
antagonism which can be applied to analysis of inhibition of
chemokine signaling by CCR5 antagonists under conditions where
CCR5 receptor levels are limiting andmaximal response to chemokine
(Emax) is reduced (Kenakin, Jenkinson, and Watson, 2006). While the
operational model described in the present study is based on the
assumption CCR5 levels are not limiting, these other models could
potentially allow analysis under conditions where receptor reserve is
limiting or interaction involves multiple CCR5 molecules. Other
models are available to accommodate changes in ligand efﬁcacy
(e.g., allosteric two state model, see (May et al., 2007)), potentially
corresponding to a model such as that described by Anastassopoulou
et al. (Anastassopoulou et al., 2009).
Overlap between the binding sites for HIV-1 envelope and
chemokine ligands on CCR5 is suggested by studies showing
inhibition of HIV-1 infection by chemokine ligands and demonstration
of inhibition of HIV infection by CCR5 antagonists that block
chemokine binding to CCR5 (reviewed in (Strizki, 2008)). Overlapin the CCR5 binding sites of HIV-1 envelope and chemokine ligand is
further supported by antibody blocking, and CCR5 mutation, studies
(Blanpain et al., 1999b; Lee et al., 1999). Modeling studies suggest that
CCR5 antagonists bind to a pocket formed by the transmembrane
domains of CCR5 and perturb the conformation of the extracellular
loops, especially extracellular loop 2 (ECL2, (Kondru et al., 2008)).
Structural studies have shown that the V3 loop of HIV gp120 also
interactswith sulfated tyrosines in theN-terminus of CCR5 (Huanget al.,
2007). Interaction of V3 with the CCR5 N-terminus contributes to virus
infectivity (Melikyan, Platt, andKabat, 2007), and recentworkbyseveral
groups indicates that resistance to CCR5 antagonists is associated with
increased dependence upon interaction with the CCR5 N-terminus
(Berro et al., 2009; Nolan et al., 2009; Ogert et al., 2009). Conceptually,
CCR5 antagonists such as VCV could act by perturbing the structure of
either ECL2 or the N-terminus, or by altering the conformation of ECL2
relative to the N-terminus, thus affecting both components of the virus
binding site. Thus, development of virus resistance to CCR5 antagonists
may be associated with decreased dependence on interaction with a
binding site composed of two elements and increased dependence on
interaction with the N-terminus.
For susceptible viruses such as JV1083-PC and RU570-PC, the effect
of CCR5 antagonists on virus infection appears to parallel the effect of
these inhibitors on chemokine binding. CCR5 antagonists produce
strong parallel shifting of the infection response curves for these
viruses, yielding dissociation constants that are consistent with
literature values and supporting the hypothesis that their suscept-
ibility to CCR5 antagonists is related to decreased afﬁnity for CCR5.
These two viruses differ in susceptibility to CCR5 antagonists although
both are “naive” to this class of inhibitors. In view of this difference as
well as differences in formats and sensitivities of assays used to
characterize susceptibility, it seems most appropriate to base a
“cutoff” for sensitivity on the relationship between assay results and
clinical response for a large number of samples rather than a selecting
a value for MPI or α based on theoretical considerations.
The resistant virus used in this study, JV1083-VCVres, was selected
from the same parental virus as the highly susceptible virus JV1083-
PC. The phenotype of JV1083-VCVres is consistent increased afﬁnity for
VCV-occupied CCR5. However, because CCR5 antagonists hadminimal
effects on JV1083-VCVres infection curves, it was not possible to obtain
reliable measurements of dissociation constants. Thus, the interpreta-
tion of α values for JV1083-VCVres as representing increased afﬁnity
for antagonist-occupied CCR5 is mainly based on comparison with α
values for JV1083-PC.
Given the complexity of virus interactionwith CCR5, it is likely that
HIV can achieve resistance through mechanisms other than increased
afﬁnity for drug-occupied coreceptor, leading to more complex
phenotypes than JV1083-VCVres. For RU570-VCVres, a relative of
RU570-PC, resistance (MPI) is dependent upon the concentration of
virus used in the assay (Ogert et al., 2009; Ogert et al., 2008). The
infection curves for this virus do not shift in parallel and cannot be ﬁt
to the model described here. In other cases, such as D1/85.16 which
has resistance mutations in gp41 (Anastassopoulou et al., 2009), the
location of mutations may be inconsistent with a major role of afﬁnity
in determining resistance. For such viruses, analysis using the ATCM-
based operational model described in this paper would not be
appropriate and other models should be considered. However, for
resistant viruses that ﬁt the criteria for the ATCM, our operational
model may allow analysis of the effects of individual resistance
mutations in terms of α, the fold change in afﬁnity for CCR5.
Materials and methods
Compounds, cells and virus stocks
Vicriviroc (VCV), maraviroc (MVC), and aplaviroc (APL) were
synthesized at Schering-Plough Research Institute (Kenilworth, NJ).
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obtained from Dan Littman (New York University, New York) and
maintained in DMEM supplemented with 10% fetal bovine serum
(FBS), 2 mM L-glutamine, 1× Pen-Strep, 1 μg per ml puromycin and
600 μg per ml G418. The PM-1 T cell line and amprenavir were
obtained through the NIH AIDS Research and Reference reagent
program (ARRP), Division of AIDS, NIAID, NIH. CCR5-tropic HIV-1
were obtained from the ARRP. PM-1 cells were maintained in RMPI
medium supplemented with 10% FBS. Susceptible viruses JV1083-PC
and RU570-PC were grown in PM-1 cells as described previously
(Ogert et al., 2008). Resistant virus JV1083-VCVres was grown on PM-1
cells in media supplemented with 10 μM VCV. Stocks of viruses were
prepared by adding 2 ml of PM-1 cell suspension from growth
cultures to T-75 ﬂasks containing 1×106 fresh uninfected PM-1 cells
in 8 ml of standard mediumwithout VCV. After 48 h, the infected PM-
1 cell suspension (approximately 10 ml) was transferred to a 15-ml
centrifuge tube containing 5 of fresh media and cells were pelleted by
centrifugation at 1250 rpm for 10 min. Cells were resuspended in
30 ml fresh media without VCV and maintained in culture for an
additional 72 h, after which infected cells were pelleted by
centrifugation and virus-containing cell supernatant was harvested
and stored as frozen aliqouts at−80 °C. Individual virus aliquots were
used once and discarded.
Single round virus infection assay
We modiﬁed the single round assay described by Mascola et al
(Mascola et al., 2002)to quantify HIV-1 infection at varying concen-
trations of virus and antagonist. U87-CD4-CCR5 cells were seeded into
96-well collagen-coated plates 24 h prior to assay. CCR5 antagonists
were prepared as 100× stocks in 100% DMSO and diluted to 1× assay
concentration in medium (1% DMSO ﬁnal). Cells were treated with
compound 2 h prior to infection. Pre-treatment medium was
aspirated, replaced with virus-containing media supplemented with
compound, and the cells were incubated at 37 °C for 2 h. Cultureswere
washed with PBS, and incubation was continued in culture medium
supplemented with compound and 2 μM amprenavir for 48 h. Cells
were harvested by trypsinization and after neutralizationwith growth
medium, transferred to 96-well V-bottom plates. Cells were centri-
fuged at 700×g for 3 min, washed with PBS and ﬁxed with 4%
paraformaldehyde (Cytoﬁx™; BD Biosciences) for 15 min. Following
ﬁxation, cells were washed twice with PBS supplemented with 0.2%
bovine serum albumin (Stain Buffer™; BD Biosciences).
Experimental design
We used a matrix design of seven virus concentrations and eight
CCR5 antagonist concentrations for each experiment. CCR5 antagonist
concentrations used were 0, 0.01, 0.1, 1, 10, 100, 1000 and 10000 nM.
Virus concentrations were generated by serial dilution and repre-
sented as decimal fractions of the virus stock, typically starting with
0.25 as the highest concentration (i.e., 0.25, 0.125, etc.). Dilutions of
virus were chosen such that the maximum concentration used would
infect no more than 40% of cells as detected by ﬂow cytometry.
Flow cytometry
For intracellular staining of p24 gag antigen, cells were centrifuged
and suspended in permeabilization buffer (Perm/Wash BufferTM; BD
Biosciences) for 15 min. Phycoerythrin (PE)-conjugated mouse anti-
p24 mAb (KC57-RD1; Beckman Coulter) was diluted to a ﬁnal
concentration of 1:160 in permeabilization buffer. Following incuba-
tion at 4° for 1 h, cells were washed 3 times, with 5 min between
washes. Stained cells were analyzed with a FACScalibur ﬂow
cytometer (BD Biosciences) and data analysis was performed with
CellQuest Pro Software (BD Biosciences). The fraction of p24 positivecells was determined by using a bivariate plot of FL-2 versus FL-1
ﬂuorescence, with the gate being set on mock infected cells. Ten
thousand events were acquired per data point.
Data analysis
Infection response data were ﬁtted to an operational model
containing functions for antagonist modulated dissociation constant
and logistic slope using the equations shown below. The fraction of
p24 antigen positive cells, fpos, was deﬁned as the number of p24
antigen positive cells (positive events detected by ﬂow cytometry)
per 10,000 cells (events) counted. A logit transform of the fractional
infection was used for ﬁtting data using the operational model. The
response variable, yexp, was deﬁned as the logarithm of the ratio of the
fraction of p24 antigen positive cells to the fraction of p24 antigen
negative cells (1− fpos):
yexp = log
fpos
1− fpos
 !
ð4:1Þ
The response calculated using the operational model, ycalc, is given by
ycalc = log
V½ nH
f0:5ð ÞnH
1 + B½ KB
1 + α B½ KB
  ð4:2Þ
where [V] is the virus concentration, [B] is the concentration of CCR5
antagonist, KB is its dissociation constant, α is the allosteric
cooperativity parameter (Ehlert, 2005; May et al., 2007) and f0.5 is
the virus concentration at which 50% of the cells are p24 antigen
positive in the absenceof CCR5 antagonist. Eqs. (4.1) and (4.2) are used
for ﬁtting the experimental data to the model, as described below.
For purposes of comparing simulated responses of different
viruses to CCR5 antagonists, it is useful to plot the data without
using the logit transform. The fraction of p24+ cells, fpos, as a function
of virus and CCR5 antagonist concentrations is given by:
fpos =
V½ nH
V½ nH + f0:5ð ÞnH
1 + B½ KB
1 + α B½ KB
  ð5:1Þ
where [(1+[B)]/KB)/(1+α[B]/KB)] represents the DR term in Eq.
(3.1) in Results. Calculation of fpos can be simpliﬁed when CCR5
antagonist concentration approaches either limit (zero or inﬁnity).
Thus, the fraction of p24+ cells in the absence of CCR5 antagonist
([B]=0) is given by
fpos; B½ =0 =
V½ nH
V½ nH + f0:5ð ÞnH
ð5:2Þ
and the fraction of p24+ cells at saturating CCR5 antagonist ([B]→∞)
is given by
fpos; B½ Y∞ =
V½ nH
V½ nH + f0:5ð ÞnHα
ð5:3Þ
Equations 5.2 and 5.1 can be used to calculate relative inhibition as a
function of CCR5 antagonist concentration:
k Inhibition =
fpos; B½ =0− fpos
fpos; B½ =0
× 100ð Þ ð6:1Þ
and Eqs. (5.2) and (5.3) can be used to calculate maximum percent
inhibition (MPI), as shown below.
MPI =
fpos; B½ −0−fpos; B½ Y∞
fpos; B½ −0
× 100ð Þ ð6:2Þ
278 P.J. Buontempo et al. / Virology 395 (2009) 268–279Curve ﬁtting by mathematical optimization
Model data, ycalc, was ﬁt to the experimental data, yexp, by
mathematical optimization to obtain a global ﬁt for the family of
response curves generated by the matrix of CCR5 antagonist and virus
concentrations used in the experiment. The values of α, nH, f0.5 and KB
were obtained by ﬁtting the calculated responses ycalc to the observed
responses yexp using the non-linear generalized reduced gradient
algorithm of Lasdon et al. (1978) incorporated in SOLVER (Frontline
Systems, Incline NV), an add-in program for Microsoft EXCEL 2002
(Microsoft, Inc., Redmond, WA).
Experimental fpos data was arranged in a 7×8 table in an EXCEL
spreadsheet using the virus concentrations as column headers and the
CCR5 antagonist concentrations as row headers. Virus concentrations
were in units of fractional dilution of stock and CCR5 antagonist
concentrations were in nM. The experimental data was used to
generate a table of yexp values calculated using Eq. (4.1), incorporating
an IF statement for each cell to accept only values of fpos≥ the limit of
quantiﬁcation (0.0005). Log virus dilution and log CCR5 antagonist
concentration were used as column and row headers, respectively, for
the yexp table. A similar table for ycalc was generated using Eq. (4.2) to
calculate each cell from the values in the column and row headers and
values for the α, nH, f0.5 and KB parameters. These parameters were
arranged in a single column table on the spreadsheet and the value of
each parameter was initialized to 1.
The SOLVER algorithm was set up to ﬁnd values of α, nH, f0.5 and
KB and such that the sum of the r2 values for all seven infection
response curves in an experiment was maximized. The coefﬁcient of
determination, r2, for the ﬁt of ycalc to yexp for each response curve
was calculated using Eq. (7.1):
r2 =
Pðyexp−yexpÞ2−Pðycalc−yexpÞ2Pðyexp−yexpÞ2 ð7:1Þ
where y¯exp is the average of the yexp values used in the ﬁt. The r2
values calculated for the ﬁt of ycalc to yexp for each concentration of
CCR5 antagonist were placed in a single column table, with the
bottom cell holding the sum of the r2 values. Mathematical
optimization was performed using SOLVER to ﬁnd values for each
cell in the parameter table such that the value of the∑(r2) cell was
maximized.
Curve ﬁtting by non-linear regression
Experimental percent inhibition data was ﬁt to a 4-parameter
logistic curve using the non-linear regression method in Prism 4.02
(GraphPad Software, San Diego, CA). The formula for the logistic curve
used in Prism is
Y = Bottom + Top − Bottomð Þ 1
1 + 10 Log10 EC50ð Þ−Xð ÞnH
 
ð8:1Þ
where the values of X are in logarithms of base 10. The upper
asymptote of the ﬁt (“Top”) was taken asmaximumpercent inhibition
(MPI). Eq. (8.1) is related to the logistic probability distribution
function.
Statistical analysis
To calculate mean values for dissociation constants, three
independent matrix-design experiments were performed for each
CCR5 antagonist and virus combination. Mean and 95% conﬁdence
intervals for KB and αwere calculated using the statistical functions in
EXCEL. For all analyses, a probability value (p) of 0.05 was taken to
indicate statistical signiﬁcance. The abbreviation “ns” (not signiﬁcant)
is used in the text to indicate comparisons for which pN0.5.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.virol.2009.09.029.
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